Boston Scientific’s (BSX) “Outperform” Rating Reiterated at Raymond James Financial

Raymond James Financial reaffirmed their outperform rating on shares of Boston Scientific (NYSE:BSX) in a research report report published on Monday, MarketBeat Ratings reports. Raymond James Financial currently has a $88.00 price target on the medical equipment provider’s stock, down from their previous price target of $97.00.

BSX has been the subject of a number of other reports. Oppenheimer reduced their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. Stifel Nicolaus decreased their target price on shares of Boston Scientific from $110.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, March 20th. Robert W. Baird lowered their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Finally, Royal Bank Of Canada reduced their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.36.

Boston Scientific Stock Down 1.2%

Boston Scientific stock opened at $62.01 on Monday. The business’s 50-day simple moving average is $75.78 and its two-hundred day simple moving average is $89.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a market cap of $92.15 billion, a PE ratio of 31.96, a PEG ratio of 0.97 and a beta of 0.78. Boston Scientific has a fifty-two week low of $61.24 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the business posted $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BSX. Steph & Co. purchased a new position in shares of Boston Scientific in the 3rd quarter valued at about $25,000. Financial Consulate Inc. purchased a new position in Boston Scientific during the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter valued at approximately $26,000. Finally, Swiss RE Ltd. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CHAMPION‑AF trial met all primary and key secondary endpoints for the WATCHMAN FLX versus NOACs — clinical data supports the WATCHMAN franchise and stroke-prevention positioning, which is bullish for long-term device revenues. Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
• Positive Sentiment: Boston Scientific completed its acquisition of Valencia Technologies — expands product pipeline/technology footprint (supports tuck‑in growth and cross‑sell opportunities). Boston Scientific completes Valencia Technologies acquisition
• Positive Sentiment: Additional clinical/data wins and study support for intravascular ultrasound (IVUS) in PCI underscore minimally invasive care leadership — a structural growth thesis for cardiovascular devices. Boston Scientific study backs use of intravascular ultrasound in PCI
• Neutral Sentiment: Some analysts reiterated positive views (RBC, Needham, Raymond James earlier reaffirmations), and long‑term bull pieces highlight durable growth — supports case for recovery if execution stabilizes. Boston Scientific (NYSE:BSX) Earns “Outperform” Rating from Royal Bank Of Canada
• Negative Sentiment: Raymond James downgraded the stock and cut estimates amid concerns about U.S. electrophysiology trends and Watchman uptake, which triggered a sharp share decline and hurt near‑term sentiment. Raymond James downgrades Boston Scientific but long-term story remains intact
• Negative Sentiment: Unusually large put‑option volume today (put buying jumped ~205%) signals elevated short‑term hedging or bearish bets from traders, adding downside pressure. Options activity report
• Negative Sentiment: Multiple law firms have filed or solicited investors for securities‑fraud class actions tied to allegations about disclosure of electrophysiology volumes and related issues — legal risk and potential litigation costs are headline negatives for sentiment. Bronstein class action notice

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.